



(12) Translation of
European patent specification

(11) NO/EP 2771031 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/00 (2006.01)
A61K 39/395 (2006.01)
C07K 16/18 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.07.23
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.04.18
(86)	European Application Nr.	12844433.8
(86)	European Filing Date	2012.10.26
(87)	The European Application's Publication Date	2014.09.03
(30)	Priority	2011.10.28, US, 201161553131 P 2012.10.08, US, 201261711208 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ME
(73)	Proprietor	Prothena Biosciences Limited, Adelphi Plaza Upper George's Street Dún Laoghaire, Co. Dublin, A96 T927, IE-Ireland
(72)	Inventor	SALDANHA, Jose, 21 Fillebrook Avenue, Enfield Middlesex EN1 3BD, GB-Storbritannia NIJJAR, Tarlochan S., 712 Ironbark Court, Orinda California 94563, US-USA
(74)	Agent or Attorney	CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

(54)	Title	HUMANIZED ANTIBODIES THAT RECOGNIZE ALPHA-SYNUCLEIN
(56)	References Cited:	WO-A1-2010/069603, WO-A1-2011/107544, WO-A2-2007/011907, WO-A2-2008/011348, LAZAR ET AL: "A molecular immunology approach to antibody humanization and functional optimization", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 8, 1 December 2006 (2006-12-01), pages 1986-1998, XP005792736, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2006.09.029, US-A1- 2009 010 924, US-A1- 2010 203 631, US-B2- 7 910 333, ELIEZER MASLIAH ET AL: "Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease", PLOS ONE, vol. 6, no. 4, 1 January 2011 (2011-01-01), pages e19338-e19338, XP055023042, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0019338, WO-A2-2008/103472

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Antistoff som binder alfa-synuklein, omfatter et variabelt domene ved en moden tung kjede med aminosyresekvensen SEQ ID No: 10, et variabelt domene ved en moden lett kjede med aminosyresekvensen SEQ ID No: 5, et konstant domene ved en tung kjede med aminosyresekvensen
5 SEQ ID No. 32 med eller uten det C-terminale lysin, og det konstante domenet ved den lette kjeden har aminosyresekvensen betegnet SEQ ID No: 13.
2. Farmasøytisk blanding som omfatter et antistoff som definert av krav 1.
3. Antistoff ifølge krav 1 for anvendelse som et medikament.
4. Antistoff ifølge krav 1 for anvendelse i behandlingen av en Lewy-legeme-sykdom (LBD).
- 10 5. Antistoff for anvendelse ifølge krav 4, hvori sykdommen er Parkinsons sykdom.